Pricing changes, regulatory decisions, coverage shifts and market exits — dated to the development, not to when we wrote it.
Released: · Last reviewed:
32 dated developments, newest first. Most recent: NexLife lowers its tirzepatide prices (2026-11-06). Items from August 2026 are kept as published.
Every item names its source and closes on what it changes for someone paying for treatment. Where a story is still moving — a proposed rule, an ongoing enforcement matter — the item says so rather than implying it is settled.
NexLife’s plan pages list compounded tirzepatide at $129 a month month to month and $125, $119 and $115 a month on 3-, 6- and 12-month plans, down from $169, $159, $149 and $139. Microdose tirzepatide moved to the same tiers on November 8.
For cash-pay patients: NexLife now matches Eden Health’s $129 month-to-month price; see every head-to-head redone.
Eden Health moved to $129 a month flat with no membership; Found prices per 28-day cycle ($359 month to month); IVIM’s one-month price is $324.99 including its program fee; Henry Meds, Remedy Meds and several others print no comparable injectable tirzepatide price; Ro, Hims & Hers and Yucca blocked our reader.
For cash-pay patients: August figures taken from third-party lists were withdrawn.
According to CNBC, Walmart will cover the two diabetes drugs at no cost for employees with type 2 diabetes in 2027, while still not covering GLP-1s for weight loss.
For cash-pay patients: employer coverage for weight loss is not expanding here; details come from news reports, not a plan document.
FDA’s page on concerns with unapproved GLP-1 drugs used for weight loss (current as of October 1, 2026) says retatrutide and cagrilintide cannot be used in compounding under federal law and gives a 28-day discard rule for compounded multi-dose GLP-1 vials.
For cash-pay patients: check the beyond-use date on any compounded vial.
Under the state’s FY2027 budget, Rhode Island Medicaid stopped covering Foundayo, Saxenda, Wegovy and Zepbound when prescribed solely for weight loss; coverage continues for type 2 diabetes and other approved uses.
For patients affected: cash-pay programs and brand self-pay are the remaining routes for weight-loss use.
CMS’s BALANCE Model page, modified September 29, 2026, includes an FAQ about “the BALANCE Model not launching in Medicare in 2027”. Medicare’s GLP-1 Bridge ($50 copay for eligible Part D enrollees for Zepbound KwikPen, Wegovy or Foundayo) runs through December 31, 2027.
For Medicare patients: the Bridge does not cover compounded tirzepatide or Zepbound vials.
FDA’s letter (posted September 22) says Empower’s compounded tirzepatide with niacinamide and semaglutide with cyanocobalamin “appear to be essentially copies” of approved products and cites insanitary conditions.
For cash-pay patients: ask which pharmacy fills your prescription and whether the formulation contains additives.
Earlier items below are dated August 2026 and kept as published.
Indian generics started near $8 a month in March. The FDA has tentatively approved a US version that cannot le…
Zepbound revenue grew well below volume, which means the average price actually paid for branded tirzepatide i…
Access expanded to roughly 20 million eligible beneficiaries, with prior authorisation reportedly running smoo…
Every correction moved the price upward, which means published cheapest figures are systematically low.…
The triple agonist clears its pivotal obesity programme. Filing is planned for Q1 2027, which puts a prescript…
Owned pharmacy, single contracted partner, or several named partners. The difference only becomes visible when…
Two of the largest consumer platforms stopped selling compounded tirzepatide during 2026, with membership bill…
Warm arrivals cluster in the hottest months, and most programmes put the judgement call on the patient.…
Fractional-dose plans at lower prices do not map onto the 2.5–15 mg ladder every comparison uses.…
If finalised, outsourcing facilities would lose a pathway for compounding at scale.…
Several programmes now split the charge into medication plus a mandatory platform fee.…
Withdrawals land mid-treatment, and interruption is the mechanism that undoes results.…
Two different problems, one outcome: an unverified substance in a syringe.…
When the platform and the pharmacy are the same business, a regulatory action lands directly on patients with …
A recurring error across round-ups, and the likely origin of several wrong figures.…
A daily tablet reaches the market at a fraction of injectable brand pricing, with a smaller effect size.…
A route that did not exist for the lowest-income patients — but optional, so it will be a patchwork.…
Following a settlement with Novo Nordisk, one of the largest platforms exits compounded semaglutide.…
The metered pen joins the vial at the same tiers, removing the syringe objection from the brand route.…
The starter dose drops to $299 and higher doses to $449, on a 45-day refill condition most coverage omits.…
Several telehealth companies were cited over labelling and marketing claims, not over patient harm.…
Multi-month discounts are real, and so is the fact that compounded medication is generally not refundable once…
Scope narrowed and large platforms exited, but patient-specific compounding continues.…
The first GLP-1 with an FDA liver indication — and a coverage route that weight management is not.…
A discrete diagnosis with an approved indication is a stronger prior-authorisation argument than a BMI thresho…
Open these rather than taking our word for it. Every one is a regulator, a trial registry, a label, an accreditor or the manufacturer.
Compare every programme on one screen
The matrix carries all-in price at every dose, fee structure, commitment terms, pharmacy disclosure and verification status for every programme we track.